Esam Zohreh, Akhavan Malihe, Lotfi Maryam, Pourmand Saeed, Bekhradnia Ahmadreza
Pharmaceutical Sciences Research Centre, Department of Medicinal Chemistry, Mazandaran University of Medical Sciences, Sari, Iran.
The Multiscale Modelling Lab, ITQB NOVA, Av. da República, 2780-157 Oeiras, Portugal.
Chem Zvesti. 2023;77(2):1129-1148. doi: 10.1007/s11696-022-02528-y. Epub 2022 Oct 21.
The current viral pandemic, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), creates health, mental, economic, and other serious challenges that are better to say global crisis. Despite the existence of successful vaccines, the possible mutations which can lead to the born of novel and possibly more dangerous variants of the virus as well as the absence of definitive treatment for this potentially fatal multiple-organ infection in critically ill patients make us keep searching. Theoretically targeting human and viral receptors and enzymes via molecular docking and dynamics simulations can be considered a wise, rational, and efficient way to develop therapeutic agents against COVID-19. In this way, The RNA-dependent RNA polymerase (RdRP), main protease, and spike glycoprotein of SARS-CoV-2 as well as the human angiotensin-converting enzyme 2 receptor and transmembrane serine protease 2 are the most discussed and studied targets that play essential roles in the viral life and infection cycle. In the current in silico investigation, the guanidine functionality containing drugs and medicinal substances such as metformin, famotidine, neuraminidase inhibitors, antimalarial medications, anticancer drug imatinib, CGP compounds, and human serine protease inhibitor camostat were studied against the above-mentioned therapeutic targets and most of them (especially imatinib) have revealed an incredible spectrum of free docking scores and MD results. The current in silico investigation that its novel perspective of view is corroborated by the different experimental and clinical evaluations, confirms that the guanidine moiety can be considered as a missing promising pharmacophore in drug design and development approaches against SARS-CoV-2. Considering the chemical potency of this polyamine group in chemical interaction creation, the observed outcomes in this virtual screening were not surprising. On the other hand, the guanidine functional group has unique physico-chemical properties such as basicity that can make the target cells intracellular pH undesirable for the virus entry, uncoating, and cytosolic lifecycle. According to the obtained results in the current study that are interestingly confirmed by the previously reported efficacy of some the guanidine carrying drugs in COVID-19, guanidine as a potential multi-target anti-SARS-CoV-2 functional scaffold deserves further comprehensive investigations.
The online version contains supplementary material available at 10.1007/s11696-022-02528-y.
当前由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的病毒性大流行,即2019冠状病毒病(COVID-19),带来了健康、心理、经济和其他严重挑战,堪称一场全球危机。尽管已有成功的疫苗,但可能出现的突变会导致产生新的、可能更危险的病毒变种,而且对于重症患者这种潜在致命的多器官感染缺乏确切的治疗方法,这使得我们仍在不断探索。从理论上讲,通过分子对接和动力学模拟靶向人类和病毒受体及酶,可被视为开发抗COVID-19治疗药物的明智、合理且有效的方法。通过这种方式,SARS-CoV-2的RNA依赖性RNA聚合酶(RdRP)、主要蛋白酶和刺突糖蛋白,以及人类血管紧张素转换酶2受体和跨膜丝氨酸蛋白酶2,是讨论和研究最多的靶点,它们在病毒的生命和感染周期中起着至关重要的作用。在当前的计算机模拟研究中,对含有胍基官能团的药物和药用物质,如二甲双胍、法莫替丁、神经氨酸酶抑制剂、抗疟药物、抗癌药物伊马替尼、CGP化合物和人类丝氨酸蛋白酶抑制剂卡莫司他,针对上述治疗靶点进行了研究,其中大多数(尤其是伊马替尼)展现出了令人难以置信的自由对接分数和分子动力学结果。当前的计算机模拟研究从新的视角进行,得到了不同实验和临床评估的证实,确认胍基部分可被视为药物设计和开发抗SARS-CoV-2方法中一个缺失的有前景的药效团。考虑到该多胺基团在形成化学相互作用方面的化学活性,在此次虚拟筛选中观察到的结果并不令人意外。另一方面,胍基官能团具有独特的物理化学性质,如碱性,这会使靶细胞内的pH值不利于病毒进入、脱壳和胞质生命周期。根据当前研究获得的结果,有趣的是,此前报道的一些含胍药物在COVID-19中的疗效也证实了这一点,胍作为一种潜在的多靶点抗SARS-CoV-2功能支架值得进一步全面研究。
在线版本包含可在10.1007/s11696-022-02528-y获取的补充材料。